Companies such as F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb (U.S.), Viatris Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Novartis AG (Switzerland), are major players in neuroendocrine tumors market.
In February 2025, The U.S. Food and Drug Administration (FDA) approved mirdametinib (Gomekli) for the treatment of neurofibromatosis type 1 (NF1) in patients who have symptomatic plexiform neurofibromas not amenable to complete surgical resection.
The countries covered in the neuroendocrine tumors market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.